Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T08:45:40.675Z Has data issue: false hasContentIssue false
  • English
  • Français

Epival

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 2 , May 1997 , pp. xxix - xxx
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

References:

1.Dean, JC. Valproate. In: Wyllie, E ed. The Treatment of Epilepsy: Principles and Practices. Philadelphia, Pa: Lea & Febiger, 1993:915–22.Google Scholar
2.Wilder, BJ, Ramsay, RE, Murphy, JV, et al. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983:33:1474–6.CrossRefGoogle ScholarPubMed
3.Turnbull, DM, Howel, D, Rawlins, MD, et al. Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J 1985;290:815–9.CrossRefGoogle ScholarPubMed
4.Covanis, A, Gupta, AK, Jeavons, PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693–720.CrossRefGoogle ScholarPubMed
5.Kakegawa, N, Miyakosni, M, Seino, M. Monopharmacy by sodium valproate (SV) and the blood concentration. In: Program and Abstracts of the XI Epilepsy International Symposium; September 30,1979; Firenze, Italy. Abstract:153.Google Scholar
6.Dreifuss, FE, Langer, DH. Side effects of valproate. Am J Med 1988;84 Suppl 1A:34–41.CrossRefGoogle ScholarPubMed
7.Epival Product Monograph. Abbott Laboratories, Limited.Google Scholar